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The genus Xenorhabdus of the family Enterobacteriaceae, are mutualistically associated
with entomopathogenic nematodes of the genus Steinernema. Although most of
the associations are species-specific, a specific Xenorhabdus sp. may infect more
than one Steinernema sp. During the Xenorhabdus–Steinernema life cycle, insect
larvae are infected and killed, while both mutualists produce bioactive compounds.
These compounds act synergistically to ensure reproduction and proliferation of the
nematodes and bacteria. A single strain of Xenorhabdus may produce a variety
of antibacterial and antifungal compounds, some of which are also active against
insects, nematodes, protozoa, and cancer cells. Antimicrobial compounds produced by
Xenorhabdus spp. have not been researched to the same extent as other soil bacteria
and they may hold the answer to novel antibacterial and antifungal compounds. This
review summarizes the bioactive secondary metabolites produced by Xenorhabdus spp.
and their application in disease control. Gene regulation and increasing the production
of a few of these antimicrobial compounds are discussed. Aspects limiting future
development of these novel bioactive compounds are also pointed out.
Keywords: Xenorhabdus, bioactive compounds, secondary metabolites, antimicrobial properties, antimicrobial
peptides
INTRODUCTION
Since the discovery of penicillin in 1928 and the introduction of sulphonamides in 1935, more than
20 classes of antibiotics entered the market (Coates et al., 2002; Powers, 2004). The majority of
these antibiotics were developed between 1940 and 1962 (Coates et al., 2011). No novel classes of
antibiotics were developed between 1968 and 1998. Antibiotics developed up to 1960 protected
humans from infections for approximately 50 years (Coates et al., 2011). Within 2 years of
marketing, resistance is usually observed, even to new classes of compounds (Bax et al., 1998).
With the current rate at which bacteria develop resistance, we may need more than 20 new classes
of antibiotics to last us for the next 50 years (thus up to 2060).
Infections caused by Gram-negative bacteria are difficult to treat and many produce metallo-
β-lactamase that neutralize carbapenems (Kumarasamy et al., 2010). Strains of Staphylococcus
aureus developed resistance to penicillin in the early 1940s, shortly after its introduction into the
market (Chambers and Deleo, 2009). Resistance to methicillin was recorded just 1 year after its
introduction. Nowadays, most of the deaths caused by S. aureus are due to MRSA (Klein et al.,
2007). Other pathogens in the so-called ESKAPE group for which new antibiotics are urgently
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needed are Enterococcus faecium, Acinetobacter baumanii,
Klebsiella pneumoniae, Pseudomonas aeruginosa, and
Enterobacter species (Rice, 2010).
Another emerging pathogen is Clostridium difficile. Infections
caused by C. difficile increased dramatically over the last
decade, especially in patients with irritable bowel disease (IBD)
(Nguyen et al., 2008). Severe cases of CDI are treated with oral
metronidazole (250–500 mg four times a day for 10–14 days), or
oral vancomycin (125–500 mg four times a day for 10–14 days).
Metronidazole is often administered intravenously, in doses of
500 mg four times daily (Persky and Brandt, 2000). Although
metronidazole is the antibiotic of choice, failure rates of 22 to 38%
have been reported and many strains have developed resistance
(Miller et al., 2010, 2011).
The rate at which bacteria develop resistance to antibiotics
depends on the genetic characteristics of the pathogen and the
mode of action of the antibiotic. For instance, resistance to
rifampicin, which inhibits DNA-dependent RNA polymerase,
develops much faster than resistance to antibiotics that target cell
membranes (Lambert, 2005; Zhanel et al., 2008). Bacteria have
several mechanisms to protect themselves against antibiotics, e.g.,
(i) inactivation of the antibiotic (e.g., production of β-lactamase
degrading the β-lactam ring in penicillins and cephalosporins),
(ii) changing membrane permeability to reduce the uptake of an
antibiotic, (iii) changing eﬄux pumps to increase the excretion of
an antibiotic from the cell, (iv) increasing production of the target
enzyme, (v) finding alternative mechanisms to bypass damaged
cell components, and (vi) altering the target site to render the
antibiotic ineffective. Some antibiotics, such as fluoroquinolones,
induce the SOS response in cells, which increases the level of
errors in DNA replication and by doing so, increases resistance
(Da Re et al., 2009).
It is evident that we need novel antibiotics to treat
bacterial infections. Oxazolidinone (linezolid by Pfizer) and
cyclic lipopeptide (daptomycin by Cubist), with activity against
Gram-positive bacteria, including MRSA, are two of the most
recent antibiotics released into the market (Coates et al., 2011).
There may be a number of yet to be published antibiotics that are
currently in preclinical development, but the overall conclusion
is that we are heading for a disaster if antibiotics with broader
antimicrobial activity are not developed in the next few years.
The rate at which novel antibiotics are being developed is just
not sufficient to control bacterial infections. We need to focus
our efforts in developing antibiotics that target complex bacterial
systems, such as cell membranes.
Xenorhabdus spp. produce various bioactive compounds
throughout their life cycle and the genus is an underestimated
and neglected source of novel bioactive compounds. All strains
live in close association with entomopathogenic nematodes
(EPNs) of the family Steinernematidae. Biologically active
compounds produced by Xenorhabdus spp. have a broad-
spectrum of antimicrobial activity, inhibiting the growth of
bacteria, fungi and protozoa, the development of insects and
nematodes, and the formation of cancerous cells (Webster
et al., 2002). The variety of bioactive compounds produced
by Xenorhabdus spp. differ, even between strains of the same
species. Polyketide synthetases (PKS) and non-ribosomal peptide
synthetases (NRPS) are responsible for the production of a
diverse group of peptides, e.g., depsipeptides (Lang et al., 2008;
Zhou et al., 2013; Kronenwerth et al., 2014), xenocoumacins
(Reimer, 2013), and PAX (peptide-antimicrobial-Xenorhabdus)
peptides (Fuchs et al., 2011). Other Xenorhabdus antimicrobial
compounds include benzylideneacetone (Ji et al., 2004), indole
derivatives (Sundar and Chang, 1993), and ribosomal-encoded
bacteriocins (Thaler et al., 1995; Singh and Banerjee, 2008).
The Steinernema life cycle is shown in Figure 1. Phase I cells
of Xenorhabdus are associated with reproducing nematodes, but
changes to phase II when nematodes infect the insect cadaver
(Akhurst, 1980). Phase I cells are larger than phase II cells,
have crystalline inclusion bodies, are mobile (by swarming), and
produce proteases, lipases, and bioactive compounds (Akhurst,
1982; Boemare and Akhurst, 1988). The two phases are
clearly distinguished by staining with bromothymol blue and
triphenyltetrazolium chloride (Kaya and Stock, 1997). Phase
I cells streaked onto growth media supplemented with a
combination of the two dyes form dark blue colonies with a
red core and are surrounded by a clear zone. Exceptions to
the rule have been reported, i.e., phase I cells not absorbing
bromothymol blue (Koppenhöfer, 2007). Nematodes infected
with Xenorhabdus enter the insect host through natural openings,
such as the mouth, anus and respiratory spiracles, and migrates
to the hemocoel. Once in the hemocoel, the nematodes enter
a feeding phase, whereupon the bacteria are released (by
defecation) and start to produce compounds to repress the
insect’s immune system (Webster et al., 2002). The protein
UnA, produced by some strains of Xenorhabdus nematophila,
prevents the hemocytes of the insect to aggregate and form
FIGURE 1 | The Steinernema life cycle. The infective juvenile (IJ) nematodes
infect an insect host and recover to the feeding phase (J3). J3 nematodes
molt into fourth phase (J4) juveniles, which in turn develop into male and
female adults. These adults reproduce and lay eggs. The eggs hatch as first
phase juveniles (J1) which feed and molt to second, third, and fourth juvenile
phases (J2–J4), and ultimately into adults. After one to three generations,
when nutrients are depleted, second phase juveniles develop into IJs (special
third phase juveniles). Each of the IJs host Xenorhabdus bacteria in their
receptacle. These IJs then leave the cadaver and await a new prey.
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capsules or nodules that would surround the nematodes and
bacteria (Ribeiro et al., 1999). Outer membrane proteins
and lipopolysaccharides produced by X. nematophila prevents
adhesion to hemocytes of Galleria mellonella Linnaeus (Dunphy
and Webster, 1991). This inhibits the activation of phenoloxidase,
an important enzyme in the insects’ immune response artillery
(Forst et al., 1997). Some strains of X. nematophila inhibits
the activity of phospholipase A2 (PLA2), which is partly
responsible for the biosynthesis of eicosanoids (Dunphy and
Webster, 1991; Park and Kim, 2000, 2003). The absence of
eicosanoids results in severe immune depression and causes
septicemia. Xenorhabdus budapestensis D43 produces a 57 kDa
insecticidal protein that activates the phenoloxidase cascade
and elicits an intense immune response in G. mellonella larvae
(Yang et al., 2012). This leads to an excessive production
of quinones, which are toxic to the larvae. X. nematophila,
Xenorhabdus japonica, Xenorhabdus kozodoii, and Xenorhabdus
beddingii cause apoptosis of insect hemocytes (Dunphy and
Webster, 1984; Brillard et al., 2001; Cho and Kim, 2004). In
the case of X. nematophila, the compound responsible for
cytotoxicity has been identified as protein CyA. Production of
these exoenzymes and toxins occur hours, killing the insect
within 24 to 48 h (Khush and Lemaitre, 2000). With the
depletion of nutrients, the juvenile nematodes switch to the
infective juvenile (IJ) stage and re-associates with the bacteria.
The nematodes then leave the cadaver in search of a new
host (Poinar, 1990; Goodrich-Blair and Clarke, 2007; Stock and
Goodrich-Blair, 2008). The genomes of Xenorhabdus spp. are
large (e.g., 4.43 Mb in the case of X. nematophila) and the cells
often harbor megaplasmids (e.g., 155 kba). Recent studies have
shown that the genomic DNA of Xenorhabdus spp. contain many
genes involved in the synthesis of insecticidal and antimicrobial
compounds (Ogier et al., 2010; Chaston et al., 2011). Recent
findings of gene rearrangements suggests that Xenorhabdus spp.
are highly adaptable to environmental changes (Ogier et al.,
2010).
Until recently, the general assumption was that a specific
Xenorhabdus sp. can only infect one Steinernema species.
Sicard et al. (2004) has shown that the fitness of Steinernema
carpocapsae improved when associated with X. nematophila, but
not when associated with non-native Xenorhabdus spp. Murfin
et al. (2015) reported an increase in the fitness of Steinernema
nematodes when infected with a strain of Xenorhabdus bovienii
native to the nematode, or when associated with a strain from
another Steinernema sp. closely related to the original nematode.
Some authors hypothesized that the association of a specific
Xenorhabdus sp. with more than one Steinernema sp. is an
indication that the respective nematodes are phylogenetically
related. The findings of Lee and Stock (2010) provided the
final answer to this hypothesis by showing that host switching
of Xenorhabdus spp. may occur within clades and between
clades, up to 17 times. Steinernema beitlechemie from the
Cameroonense-clade (Çimen et al., 2016) is associated with
Xenorhabdus khoisanae. However, X. khoisanae was first isolated
from Steinernema khoisanae of the Glaseri-clade (Nguyen et al.,
2006; Ferreira et al., 2013). In a more recent paper, further
evidence of X. khoisanae switching between clades was reported
when the species was isolated from Steinernema sacchari of the
Cameroonense-clade (Dreyer et al., 2017).
Steinernema nematodes infected with Xenorhabdus spp. is
a highly effective natural way of controlling insect pests.
Steinernema yirgalemense infected with a few as 50 infected
juvenile nematodes (IJs) caused 100% mortality of false codling
moth (Thaumatotibia leucotreta, Meyrick) larvae (Malan et al.,
2011). Other studies have shown similar results against mealy
bugs (Planococcus ficus, Signoret) (Le Vieux and Malan, 2013),
sugarcane stalk borer (Eldana saccharina, Walker) (Pillay et al.,
2009), fruit flies Ceratitis capitate (Wiedemann) and Ceratitis rosa
(Karsch) (Malan and Manrakhan, 2009; James et al., 2018).
SECONDARY METABOLITES
PRODUCED BY Xenorhabdus SPECIES
Xenorhabdus bacteria are known to produce broad-spectrum
compounds with activity against bacteria, fungi, insects,
nematodes, protozoa, and cancer cells (Webster et al., 2002).
These activities each play a unique role in the protection and
bioconversion of the host cadaver, and promote reproduction
and growth of the nematodes. Paul et al. (1981) identified several
novel antibacterial compounds produced by Xenorhabdus spp.
Since this discovery, various additional bioactive Xenorhabdus
compounds have been reported. Fodor et al. (2012) summarized
novel antimicrobial peptides produced by Xenorhabdus
szentirmaii and X. budapestensis, and focused mostly on the
effect these peptides have on the plant pathogens Agrobacterium,
Burkholderia, Clavibacter, Curtobacterium, Dyckeya, Erwinia,
Pectobacterium, Ralstonia, Pseudomonas, Xanthomonas,
Phytophthora, Pythium, Botrytis, Alternaria, and Fusarium
species.
Only a few papers have been published on the regulation
of antimicrobial compounds produced by Xenorhabdus spp. In
X. nematophila, the leucine responsive protein (lrp) plays a
role in regulating symbiosis with nematodes and pathogenicity
to insects (Cowles et al., 2007; Hussa et al., 2015). Lrp
may also be involved in regulating antibiotic production, as
strains without the lrp gene had no antimicrobial activity
toward Micrococcus luteus and Bacillus subtilis (Cowles et al.,
2007). In the case of Photorhabdus luminescens, lrp led to
the overproduction of desmethylphurealipid A. Injection of
desmethylphurealipid A into G. mellonella and Manduca sexta
larvae reduced the mRNA levels for antimicrobial-peptide-
encoding genes, suggesting that these molecules may play a
role in insect pathogenicity (Nollmann et al., 2015). Based on
results obtained with microarray analyses (Engel et al., 2017),
lrp regulates genes encoding the biosynthesis of xenematides,
xenortides, rhabdopeptides, xenocoumacins and PAX-peptides,
as well as six other genes with an unknown biosynthetic
function. In Salmonella enterica, the LysR-type transcriptional
regulator protein (LeuO) acts as a repressor for SPI-1 (Salmonella
pathogenicity island) and is often described as an antagonist
of heat-stable nucleoid-structuring protein (H-NS) (Chen and
Wu, 2005; Espinosa and Casadesús, 2014). In Vibrio cholerae,
LeuO is part of the ToxR (a membrane-spanning transcription
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factor) regulon and down-regulates important virulence factors.
In X. nematophila and P. luminescens LeuO is described as a
regulator for virulence factors and plays a role in the regulation
of natural products. LeuO attenuates the production of most
examined natural products, including nematophin, an antifungal
and antibacterial peptide (Li et al., 1997a). Xenocoumacins,
xenematides, and xenortides display antimicrobial activity
against a broad spectrum of bacteria (Lang et al., 2008) and help
eliminate microorganisms from the insect cadaver. Xenematides
have insecticidal activity, rhabdopeptides are active against insect
hemocytes (Lang et al., 2008; Reimer et al., 2013), and xenortides
are cytotoxic against mammalian L6 cells (Reimer et al., 2014).
These antimicrobial compounds are often produced at very
low concentrations. Production levels may be scaled up by
exchanging the promoters in front of biosynthesis genes with
stronger or constitutive promoters (Bode et al., 2015), clone the
genes into a replicative overexpression plasmid, or express the
biosynthesis genes in different hosts (Schimming et al., 2014).
Engel et al. (2017) reported that expression of the LeuO regulator
of X. nematophila in X. szentirmaii led to overproduction of
the GameXPeptide. The authors have also shown that this may
lead to the production of antimicrobial compounds normally not
produced by the natural host.
Several classes of structurally diverse secondary metabolites
with a broad spectrum of bioactivity, including insecticidal,
antifungal, antibacterial, nematicidal, and cytotoxicity, have been
isolated from different Xenorhabdus strains (Brachmann and
Bode, 2013). These include depsipeptides such as xenematides,
xenocoumacins, fabclavines, pristinamycin, xenortides,
rhabdopeptides, bicornitun, PAX peptides, cabanillasin,
nemaucin, dithiolopyrrolone derivatives, indole-containing
compounds, benzylideneacetone, rhabduscin, bacteriocins
and a few unnamed peptides (Table 1). The diverse profile
of bioactive compounds produced by Xenorhabdus spp. is
supported by the large variation in gene clusters (as many as
23; Reimer et al., 2014). The secondary metabolic compounds
produced by the Xenorhabdus spp. included in this review,
and the accession numbers of the respective genome and gene
sequences listed in GenBank, are included in Table 1. The
molecular structures of the bioactive compounds are shown in
Figure 2. Despite the large variation in bioactive compounds,
none have been commercialized in chemical form. However,
several applications of nematodes associated with Xenorhabdus
symbionts have been used as biological control agents (Ehlers,
2001; Chavarría-Hernández et al., 2010).
Depsipeptides
Depsipeptides are peptides with one or more amide group
replaced by a hydroxy acid, leading to the formation of an
ester bond. These peptides generally contain alternating peptide
and ester bonds. Thus far, five classes of depsipeptides have
been described. The first class, classified as xenoamicin, are
tridecadepsipeptides with hydrophobic amino acids and are
produced by Xenorhabdus doucetiae and Xenorhabdus mauleonii
(Zhou et al., 2013). Concluded from the genome sequence of
X. doucetiae DSM 17909, xenoamicins are encoded by five
non-ribosomal peptide synthetases (NRPSs), XabABCD and an
aspartic acid decarboxylase (XabE). Thirteen modules within
XabABCD have been linked to the synthesis of xenoamicin.
XabE is involved in the formation of β-alanine. Based on
the hydrophobic characteristics, xenoamicin interacts with the
cytoplasmic membrane. However, no antibacterial or antifungal
activity has been recorded for xenoamicin A, which implies a
different mode of activity. Anti-protozoal and weak cytotoxic
activities have been reported for xenoamicin A, but the target sites
have not been identified.
The second class of depsipeptides, the lipodepsipeptides, has
an additional fatty acid chain attached to one of the amino acids
and is produced by Xenorhabdus indica (Kronenwerth et al.,
2014). The peptides are named after their amino acid sequence,
T-A-X-L-L-L-A (X = L, F, or Y), and are referred to as taxlllaids
(A-G). Seven variants were described, each classified based on
the length of the fatty acid chain, the third amino acid and the
overall structure of the molecule, i.e., an open chain or ring
structure. The synthesis of taxlllaids are encoded by a gene cluster
consisting of two NRPSs, and TxlA and TxlB, with four and three
modules, respectively. Natural taxlllaid A and synthetic taxlllaids
B-G have antiprotozoal activity. Taxlllaid A is also cytotoxic to
human carcinoma cells (HeLa) (Kronenwerth et al., 2014).
The third class of depsipeptides are classified as indole-
containing xenematides. Xenematide A was the first example,
isolated from X. nematophila (Lang et al., 2008). The molecule
is cyclic, antibacterial and weakly insecticidal. Three years
later, Crawford et al. (2011) isolated three more xenematides
(B–D) from X. nematophila and showed with gene knockout
studies that XNC1_2713 encodes the production of xenematide
A. Xenematides are not restricted to X. nematophila or the
genus Xenorhabdus, as protein homologs have been identified in
X. bovienii and Photorhabdus asymbiotica.
The final two depsipeptide classes consist of xenobactin and
szentiamide (Nollmann et al., 2012; Grundmann et al., 2013).
Xenobactin was isolated from an unknown Xenorhabdus sp.,
strain PB30.3, and szentiamide from X. szentirmaii. Both peptides
are active against Plasmodium falciparum and have some activity
against Trypanosoma brucei rhodesiense and Trypanosoma cruzi.
Szentiamide does not have any antibacterial or antifungal activity,
but has a weak cytotoxic activity against G. mellonella hemocytes.
Contrary to szentiamide, xenobactin has no cytotoxic activity,
but is active against M. luteus. The antibacterial activity is likely
due to the hydrophobic nature of the peptide and the target in
M. luteus is most probably the cell membrane.
Xenocoumacins
Xenocoumacins, first described by Mclnerney et al. (1991a), have
benzopyran in the amino acid chain and are mostly produced by
X. nematophila. Xcn1 is active against Gram-positive and Gram-
negative bacteria, and has antifungal and anti-ulcer activity. Xcn2
has less antibacterial activity and no antifungal activity, but
has anti-ulcer activity. More recently, Reimer (2013) discovered
that Xcn2 is produced from Xcn1 through reactions encoded
by genes xcnM and xcnN. In a study conducted by Park et al.
(2009), the xcnM gene was inactivated, which led to an increased
Xcn1 level, as expected, but also decreased cell viability 20-
fold. The conversion of Xcn1 to Xcn2 was therefore suggested
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TABLE 1 | Genome and gene assemblies of Xenorhabdus spp. and production of secondary antimicrobial compounds.
Species DNA assembly Secondary metabolic compound
described
Reference
X. beddingii MUBK00000000 R-type bacteriocins Akhurst, 1986a,b; Boemare et al., 1992
X. bovienii FN667741 Amicoumacin, xenomin, xenorxid,
xenorhabdin, xenematide
Chaston et al., 2011; Sugar et al., 2012; Park et al., 2016
X. budapestensis NIBS01000000 Fabclavine, bicornitun, unnamed
peptide
Böszörményi et al., 2009; Xiao et al., 2012; Fuchs et al.,
2014; Tobias et al., 2017
X. cabanillasii NJGH01000000
CBXE00000000
Nemaucin, cabanillasin, rhabdopeptide Gualtieri et al., 2009; Houard et al., 2013; Reimer et al.,
2013
X. doucetiae FO704550, FO704549 Xenoamicin, xenocoumacin,
xenorhabdin
Zhou et al., 2013; Bode et al., 2017
phenylethylamine, tryptamide
X. indica Lipodepsipeptide Kronenwerth et al., 2014
X. japonica FOVO00000000 Nishimura et al., 1994
X. khoisanae LFCV01000000 Crawford et al., 2012
X. kozodoii NJCX01000000 Xenocoumacin Reimer et al., 2009; Tobias et al., 2017
X. mauleonii NITY01000000
FORG00000000
Xenoamicin, xenocoumacin,
xenorhabdin
Zhou et al., 2013; Tobias et al., 2017
X. nematophila FN667742, FN667743,
LN681227, LN681228,
JRJV00000000,
CCWW00000000,
Rhabduscin (putative gene cluster
sequenced)
Chaston et al., 2011; Crawford et al., 2012; Lanois et al.,
2013; Hong et al., 2015
CCWM00000000,
CAVM00000000
Pristinamycin Brachmann et al., 2012; Shi and Bode, 2018
Xenocoumacin
(gene cluster xcnA–xcnN sequenced)
Mclnerney et al., 1991a; Lang et al., 2008; Park et al.,
2009; Reimer et al., 2009; Guo et al., 2017
Xenematide Lang et al., 2008; Crawford et al., 2011
Rhabdopeptide (peptides rdpA, B, and
C sequenced)
Reimer et al., 2013
PAX peptide
(peptides xpsA, xpsB, and xpsD
sequenced)
Gualtieri et al., 2009; Crawford et al., 2010; Fuchs et al.,
2011
Oxindole and benzylideneacetone Seo et al., 2012
Nematophin Li et al., 1997a,b; Lang et al., 2008; Crawford et al., 2011;
Reimer et al., 2014
Xenortide (peptides NRPS XndA and B
sequenced)
Lang et al., 2008
Xenorhabdicin Thaler et al., 1995; Morales-Soto and Forst, 2011;
Morales-Soto et al., 2012
Xenocin (peptide xcinA sequenced) Singh and Banerjee, 2008
X. szentirmaii Genome assembly
NIUA01000000
NIBV01000000
CBXF00000000
Fabclavine, szentiamide Fodor et al., 2012 Nollmann et al., 2012; Grundmann et al.,
2013; Fuchs et al., 2014; Tobias et al., 2017
References are key papers on species. For DNA sequences, refer to GenBank. Genome accession numbers were obtained from GenBank [as listed in the
PATRIC database, https://www.patricbrc.org/view/Taxonomy/626#view_tab=genomes&filter=eq(genome_status,∗)]. Underlined accession numbers: complete genome
sequence. Peptide sequences deposited are listed.
to be a mechanism used by the bacteria to avoid self-toxicity.
Xcn1 is modified by various reactions to produce Xcn2, Xcn3,
Xcn4, Xcn5, and Xcn6. The latter four were isolated from
X. nematophila and X. kozodoii (Reimer et al., 2009).
Fabclavines
Fabclavines, or peptide-polyketide-polyamino peptides, are
produced by X. budapestensis and X. szentirmaii and are
encoded by a combined PKS-NRPS gene cluster (Fuchs et al.,
2014). The peptide moiety is synthesized by the FclI and FclJ
NRPSs, while in the PKS, FclK is responsible for catalyzing
the elongation of the peptide moiety’s proline residue. These
peptides are active against Gram-positive and Gram-negative
bacteria, Saccharomyces cerevisiae, Plasmodium falciparum,
Trypanosoma brucei, and Trypanosoma cruzi. Fabclavines and
cationic antimicrobial peptides are structurally very similar.
The latter displayed increased activity when combined with
antibiotics (Hancock, 2001).
Pristinamycin
Pristinamycin forms part of the streptogramin A family of
antibiotics and was until recently known to be produced by
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FIGURE 2 | Continued
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FIGURE 2 | Xenorhabdus bioactive compounds. Bioactive compounds with unknown structures include the antibacterial xenoprotec, bicornituns C and D, and the
two bacteriocins, xenorhabdicin, and xenocin. Compiled from Boemare et al. (1992), Paik et al. (2001), Hwang et al. (2003), El-Hag and El-Sadawy (2008), Gaultieri
et al. (2012).
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streptomycetes only. Pristinamycin consists of approximately
30% pristinamycin I and 70% pristinamycin II. Component
II occurs in two forms, pristinamycin IIA and IIB, of which
IIA is the most abundant (Blanc et al., 1995). Pristinamycin
IIA is also produced by X. nematophila and is encoded by
PKS/NRPS (Brachmann et al., 2012). The biosynthetic gene
clusters in X. nematophila and Streptomyces pristinaspiralis are
very similar. Interestingly, further analysis of X. nematophila
showed that it does not contain a gene cluster for the biosynthesis
of pristinamycin IA. The pxn (pristinamycin IIA, X. nematophila)
gene cluster, however, is associated with transposases, suggesting
that the genes were obtained through horizontal gene transfer.
This might explain the absence of the pristinamycin IA gene
cluster in X. nematophila.
Xenortides
To date, four xenortides, namely xenortides A–D, have been
identified from X. nematophila (Lang et al., 2008; Crawford et al.,
2011; Reimer et al., 2014). These peptides are biosynthesized
by a gene cluster consisting of two NRPS genes (xndA and
xndB). Xenortides have weak antiprotozoal activity, with the
tryptamides (xenortides B and D) being more active than the
phenylethylamides (xenortides A and C), and xenortide B being
the most active (Reimer et al., 2014).
Rhabdopeptides
Rhabdopeptides are linear, non-ribosomally produced, and
structurally similar to xenortides. A total of eight rhabdopeptides
have been identified, rhabdopeptides 1, 2, 3, and 4 are from
X. nematophila, and 7 and 8 from Xenorhabdus cabanillasii
(Reimer et al., 2013). Rhabdopeptide 2 has weak cytotoxic activity
against myoblasts. Rhabdopeptides 2, 7, and 8 have antiprotozoal
activity, and 7 and 8 are weakly hemotoxic. These peptides are
produced at high concentrations 4 days after infection, but levels
stagnate after 10 days, suggesting that they are important during
the insect bioconversion and nematode reproduction stages. The
gene cluster responsible for the biosynthesis of these peptides
consists of a three-module NRPS gene, RdpABC.
Bicornitun
Xenorhabdus budapestensis produce the arginine rich, bioactive
compounds bicornitun A1, A2, B, and C (Böszörményi et al.,
2009). The NRPS responsible for the production of bicornitun
A1 was identified as BicA. This was determined by cloning the
bicA gene, which encodes BicA, into an expression vector and
expressing bicornitun A1 in Escherichia coli (Fuchs et al., 2012).
The bicornitun complex (a combination of bicornitun A–C) is
cytotoxic toward Phytophthora nicotianae by inhibiting colony
formation, as well as mycelial growth. Erwinia amylovora and
Bacillus subtilis is also susceptible to the bicornitun complex.
PAX Peptides
PAX peptides 1 to 5 were first identified by Gualtieri et al. (2009)
and described as lysine-rich cyclolipopeptides. These peptides,
produced by X. nematophila, have antifungal and antibacterial
activity. However, they do not show cytotoxic activity and did
not lead to increased mortality when injected into insects. An
additional eight PAX peptides were identified and their structures
elucidated by Fuchs et al. (2011). Three NRPS genes (paxABC)
are responsible for the biosynthesis of the PAX compounds.
The three NRPSs (PaxA, PaxB, and PaxC) contains 3, 9, and 10
domains, respectively.
Cabanillasin and Nemaucin
The peptides cabanillasin and nemaucin were isolated from
X. cabanillasii. Cabanillasin was efficient at inhibiting the growth
of human pathogenic filamentous fungi and yeasts (Houard
et al., 2013). Nemaucin was, active against methicillin resistant
S. aureus (MRSA). Common genes may be involved in the
production of these two peptides, as both have four units of the
amino-1 guanidino-butane moiety and are produced by the same
organism. Nemaucin is, however, structurally more similar to
fabclavine 1a from X. budapestensis than cabanillasin, and differs
only by having a shorter C-terminal (Fuchs et al., 2014).
Dithiolopyrrolone Derivatives
These derivatives include the two metabolites, xenorhabdins
and xenorxides. Xenorhabdins have a typical heterobicyclic
pyrrolinonodithiole core, which is characteristic of
dithiolopyrrolone compounds (Challinor and Bode, 2015).
Xenorxides, in turn, are structurally similar to xenorhabdins and
are produced when the sulfur moiety of xenorhabdins is oxidized
(Webster et al., 1996). Xenorhabdins and xenorxides have
antibacterial, antifungal and insecticidal activities (Mclnerney
et al., 1991a,b; Li et al., 1995). Some of these dithiopyrrolone
derivatives have anticancer properties. The suggested mode of
action is inhibition of RNA synthesis (Joshi et al., 1982; Oliva
et al., 2001).
Indole-Containing Compounds
Indole is an aromatic heterocyclic compound, consisting of
a fused pyrrole- and benzene ring (Sainsbury, 2001). Various
bacterial species produce indole and indole derivatives that
play a role in the regulation of bacterial physiology (Lee and
Lee, 2010). Indole derivatives isolated form X. nematophila
and X. bovienii are active against Gram-positive and Gram-
negative bacteria, as well as fungi. Sundar and Chang (1993)
studied these compounds and found the mode of action the
inhibition of RNA synthesis. Growing bacteria have a relatively
narrow range of ppGpp concentrations and indole derivatives
increase this concentration, leading to a reduction in RNA
synthesis and, ultimately, a reduction in growth rate. Seo et al.
(2012) identified the indole-containing compound, oxindole,
as well as indole, also produced by X. nematophila. These
compounds have weak phospholipase A2 inhibitory effects. As
mentioned elsewhere, phospolipase A2 is an enzyme required
for the production of eicosanoids. Eicosanoids, in turn, are
crucial for activating an immune response in the insect by
modulating and mediating hemocyte behavior (Shrestha and
Kim, 2007). It is thus safe to assume that indole-containing
compounds inhibit the immune response of the insect, making
it more susceptible to microbial infection. Proschak et al.
(2014) identified additional indole derivatives, xenocycloins
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(A-E), also produced by X. bovienii. These compounds have
no antibacterial activities, but xenocycloins B and D are
active against G. mellonella hemocytes. Xenocyloins therefore,
also contribute to the insecticidal activity of these bacteria.
Xenematides, discussed under depsipeptides, are also known to
contain the indole structure.
Another indole containing compound, nematophin, is highly
active against MRSA strains (Li et al., 1997a). In a study
conducted by Li et al. (1997b), minimal inhibitory concentrations
of nematophin and its derivatives against S. aureus strains
were determined and it was proven that compounds with an
α-carbonyl acyl group inhibited the growth of S. aureus. However,
compounds where the α-carbonyl acyl group was reduced
or transferred to a corresponding α-methoximino acyl group,
bioactivity decreased or disappeared. It was therefore suggested,
that this α-carbonyl acyl group is essential for the bioactivity of
these compounds.
Unnamed Peptides
Two antimicrobial peptides, GP-19 and EP-20, have been isolated
from X. budapestensis (Xiao et al., 2012). These peptides show
broad-spectrum antimicrobial activity against fungi and bacteria,
but the mode of action is yet to be unraveled. GP-19 has a
neutral charge and is proposed to cause a disruptive effect on
the membrane by mobilizing to the cell surface and possibly
penetrating the membrane. As EP-20 has a negative charge it
most likely does not have the same mode of action. This peptide
is proposed to have an intracellular effect, by inhibiting cell wall,
nucleic acid, and protein synthesis.
Benzylideneacetone
The moderately hydrophobic compound, benzylideneacetone,
isolated from X. nematophila, is active against Gram-negative
plant pathogenic bacteria. This compound has been used in the
industry for various applications, including as a flavoring additive
in soaps, cosmetics, detergents and cigarettes, as well as a food
additive in candy, gelatin, and puddings. Even though it has
been used for some time, it was only discovered in 2004 to have
antibacterial activity (Ji et al., 2004). Benzylideneacetone also
inhibits phospholipases A2, which, as described, results in the
inhibition of the immune response of the insect (Seo et al., 2012).
Rhabduscin
Rhabduscin is an insecticidal tyrosine derivative, produced by
X. nematophila. The insecticidal activity of this compound is
achieved by inhibiting the enzyme phenoloxidase to a low
nanomolar-level with an IC50 measurement of approximately
64.1 nM. Phenoloxidase is important in the melanization
pathway of the insect’s immune system. Inhibition thereof leads
to inhibition of one of the primary innate immune responses
(Crawford et al., 2012).
Bacteriocins
Xenorhabdus bacteria also produce bacteriocins, for example,
xenocin, which is produced by X. nematophila. Interestingly,
the antibacterial activity of xenocin was only observed when
bacterial strains were grown in minimal medium and not in
enrichment medium such as Luria or nutrient broth. Xenocin
production is triggered by a low iron concentration. The role
of iron depletion has been proposed to be linked to an iron
repressed protein, which may act as a toxin receptor on sensitive
bacterial strains. This bacteriocin is therefore, only produced
in the host larva when nutrient concentrations are low and
competition intensifies (Singh and Banerjee, 2008). Another
bacteriocin, produced by X. nematophila as well as X. bovienii,
the phage tail-like xenorhabdicin, is bactericidal (Thaler et al.,
1995; Morales-Soto et al., 2012). Xenorhabdus owes its activity
against closely related bacteria to these bacteriocins, which are
essential for keeping the environment free of other Xenorhabdus
spp. and its sister genus, Photorhabdus spp. X. beddingii is also
able to produce bacteriocins, however these bacteriocins have not
been characterized.
UPREGULATING THE PRODUCTION OF
Xenorhabdus ANTIMICROBIALS
When producing antibiotics, it is of the utmost importance that
the fermentation conditions are optimal to avoid the squandering
of time and money. Antibiotic production in Xenorhabdus
has been optimized at various time periods, mostly by one
research group from the Northwest University of Agriculture and
Forestry, China. This group focused on antibiotic production
by X. bovienii YL002 (Fang et al., 2012) and, X. nematophila
TB (Fang et al., 2010) and YL001 (Wang et al., 2008), while
another group focused on a specific X. nematophila strain isolated
from S. carpocapsae BJ (Xiufen et al., 2001). Factors taken
into consideration for these studies were the environmental
parameters; initial medium pH, temperature, rotary speed,
inoculation volume, medium volume in flask, fermentation time,
dissolved oxygen levels, and growth media.
As expected, the optimization for specific strains varies.
There are, however a few trends in the results of these
studies. The optimal fermentation conditions are a pH from
6.0 to 8.24, temperature of 25–32◦C, rotary speed of 150–
220 rpm, inoculation volume of 4–15%, medium volume of
54–100 ml/250 ml flask and a fermentation time of 54–72 h. The
dissolved oxygen level was tested for only X. nematophila YL001
and was optimal when it was shifted during fermentation from
70% after the first 18 h to 50% for the remaining 54 h. The optimal
growth media was tested for X. nematophila TB and X. bovienii
YL002, however, the ingredients and amount of each ingredient
differs for the respective recipes.
Crawford et al. (2010) identified one of the main compounds
that leads to increased small metabolite production in
X. nematophila. Xenorhabdus bacteria are known to produce
higher concentrations of bioactive compounds when in
G. mellonella hemolymph than grown in vitro (Maxwell
et al., 1994). Therefore, it was hypothesized that one or more
compounds present in insect hemolymph are responsible for
activating the production of bioactive compounds. This led to the
selective purification of G. mellonella hemolymph, which led to
the discovery of proline as the activating signal. Supplementing
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bacterial cultures with D-proline did not increase the production
of bioactive compounds, however, L-proline did. L-proline is
thought to be a generic activating signal as it is present in various
insect larvae.
The addition of L-proline to bacterial cultures led to an
increase in xenematide, three indole derivatives and rhabduscin
biosynthesis. Another indole-containing compound that was
affected by an increase in L-proline is nematophin. This L-proline
increase led to a decrease in the production of nematophin but an
increase in its reduced derivative. L-proline therefore, regulates a
metabolic shift in this case, rather than an increase in nematophin
production.
It is evident that production of bioactive compounds requires
optimization of the production protocol. This is necessary both
for use in industry, as well as in research. The optimization
process is however not an easy task and extended research is
needed for this process, especially since the protocol will be
specific for each bacterial strain and product desired.
CONCLUSION
Even though Xenorhabdus is not one of the generally known
antimicrobial metabolite sources, it is clear to see why Pidot
et al. (2014) refer to it as a neglected antibiotic source. It is
evident that Xenorhabdus bacteria are an excellent source for
novel antimicrobial metabolites. Various studies (Barkai-Golan,
2001; Böszörményi et al., 2009; Shapiro-Ilan et al., 2009; Fang
et al., 2011), have revealed the significant potential of these
bioactive secondary metabolites not only in vitro, but also in vivo.
These studies investigated the use of these compounds in only
the agricultural industry. However, these compounds may also
be exploited in various other industries, including the healthcare
and food industries.
A number of papers have been published on Xenorhabdus
bacteria and their bioactive compounds. However, this is only
the tip of the iceberg. A study done by Crawford et al. (2010),
stated that the X. nematophila DSM 3370T genome contains
various gene clusters encoding small molecule antimicrobial
metabolites. The number of potential metabolites estimated
to be produced by this bacterium vastly exceeds the amount
of known antibiotic metabolites. Furthermore, it is generally
known that different Xenorhabdus species, and even strains,
produce different bioactive compounds. Therefore, it is clear that
the possibilities regarding novel bioactive compounds produced
by Xenorhabdus bacteria are virtually endless. Furthermore,
taking into consideration the current antibiotic resistance crisis,
novel antibiotic discovery is of the essence and Xenorhabdus
bacteria might hold the key to human survival in the 21st
century.
Although the possibilities of discovering novel antimicrobial
compounds from Xenorhabdus spp. is promising, methods
need to be developed to produce these compounds at much
higher concentrations. This may be difficult, as most of
these antimicrobial compounds are produced non-ribosomally
and are thus not a single gene product. However, increased
production will follow as we gain more insight on the
control of the metabolic pathways. Further research is
also required on the effect different growth media and
nutrients may have on the production of these bioactive
compounds.
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